Edesa Biotechの内部者の所有権

Edesa Biotechの内部者の所有権は何ですか。

Edesa Biotech, Inc.の内部者の所有権は21.83%です。

内部者の所有権の定義は何ですか。



管理の所有権(Insider Ownership)は、発行済株式総数で除したインサイダー(5%超を所有する株主または取締役または役員) が所有する株式総数によって計算されます。

A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.

A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.

NASDAQのセクタHealth Careにおける内部者の所有権の企業と比べるEdesa Biotech

Edesa Biotechは何をしますか。

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Edesa Biotechと類似の内部者の所有権